The Problem
When checkpoint inhibitors stop working, patients need new options.
Checkpoint inhibitors have transformed melanoma treatment, but many patients do not respond or eventually relapse. Claredele is focused on this critical gap in care: resistant melanoma, where treatment options remain limited and no approved therapies directly address checkpoint inhibitor resistance.
-
Melanoma remains the most lethal skin cancer and a growing global burden.
-
About half of patients fail to benefit meaningfully from checkpoint inhibitors.
-
There are no approved therapies specifically designed to overcome ICI resistance.
The Solution
A differentiated approach to overcoming resistance.
PMJ2 is Claredele’s lead small-molecule immunotherapy designed to restore sensitivity to checkpoint inhibitors. In preclinical melanoma models, PMJ2 has shown tumor growth inhibition, selective toxicity toward tumor cells, increased immune-cell infiltration, and memory T-cell responses associated with durable immunity.
-
Reprograms the tumor microenvironment.
-
Enhances checkpoint inhibitor efficacy.
-
Small-molecule, non-viral, scalable approach.
About us
Science-driven immunotherapy innovation, grounded in personal experience.
Claredele is an early-stage oncology company focused on overcoming resistance to checkpoint inhibitor therapy so more patients can benefit from immunotherapy. Our lead program, PMJ2, is a first-in-class small-molecule immunotherapy designed to restore sensitivity to checkpoint inhibitors, beginning in melanoma with the potential to reach additional resistant cancers over time.
Get in touch
We welcome inquiries from investors interested in early-stage oncology innovation and the development of PMJ2 for resistant melanoma and beyond.